Japanese guidelines for atopic dermatitis 2020

Katoh, Norito; Ohya, Yukihiro; Ikeda, Masanori; Ebihara, Tamotsu; Katayama, Ichiro; Saeki, Hidehisa; Shimojo, Naoki; Tanaka, Akio; Nakahara, Takeshi; Nagao, Mizuho; Hide, Michihiro; Fujita, Yuji; Fujisawa, Takao; Futamura, Masaki; Masuda, Koji; Murota, Hiroyuki; Yamamoto‐Hanada, Kiwako

doi:10.1016/j.alit.2020.02.006

Cited by 139 publications

(214 citation statements)

References 65 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…Thymus-and activation-regulated chemokine -TARC/ CCL-17 is a ligand of a specific chemokine receptor CCR4, which promotes the targeted migration of Th2 cells that provide a humoral immune response to antigens, including those of an allergic nature. This chemokine has been intensively studied in Japan since 2008, and as of 2020, it is included in the Japanese recommendations [9] as a biomarker for the diagnosis and assessment of the severity of patients with atopic dermatitis. Its role in the development of allergic diseases such as allergic rhinitis and bronchial asthma has been proven in scientific works.…”

Section: Resultsmentioning

confidence: 99%

Ways of Optimizing the Diagnostics of Food Allergies in Children Based on the Clinical and Immunological Criteria

et al. 2020

View full text Add to dashboard Cite

The aim of the research was to investigate the spectrum of food sensitization, followed by the determination of the main clinical criteria and immunological markers of food allergy in children with gastroduodenal pathology and atopic dermatitis. Materials and methods: We conducted a comprehensive clinical and immunological examination of 120 children aged from 6 to 15 years with gastroduodenal pathology (group 1; n = 64) and atopic dermatitis (group 2; n = 56), who had a history of adverse allergic reactions to food. The control group consisted of 22 apparently healthy children. Results: In the group of children with gastroduodenal pathology, the spectrum of the most common significant food allergens was represented by legumes, the reaction to which was observed in 25 (39.1%) subjects, eggs (25.0%) and fish (23.4%), which were found in every fourth child. Among patients with atopic dermatitis, the leading positions were occupied by fruits, which were registered in 20 (35.7%) children, nuts – in 15 (26.8%), honey and vegetables – in 11 (19.6%) children, respectively. The study of immunological status in comparison with the control group revealed reliable increases in pro-inflammatory T-helper-2 cytokines – interleukin-4 and chemokine TARC/CCL-17 and a simultaneous decrease in anti-inflammatory interleukin-10 in children of the 1st and 2nd groups who had gastrointestinal and skin manifestations of allergic reactions when eating food products. Conclusions: The study of peculiarities of adverse reactions to food in the examined children allowed us to identify specific clinical criteria and immunological markers of food allergy, which had certain features depending on the skin or gastrointestinal manifestations.

show abstract

Section: Resultsmentioning

confidence: 99%

Ways of Optimizing the Diagnostics of Food Allergies in Children Based on the Clinical and Immunological Criteria

et al. 2020

View full text Add to dashboard Cite

show abstract

“…AD was diagnosed in accordance with the criteria in the Guidelines for Atopic Dermatitis. 29,30 Disease activity in AD patients was assessed by EASI score. Moderate to severe AD patients were mainly enrolled in the study and their median EASI score was 18.5 (Table S1).…”

Section: Study Populationmentioning

confidence: 99%

Activated steady status and distinctive FcεRI-mediated responsiveness in basophils of atopic dermatitis

Imamura

Washio

Mizuno

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: Although basophils are considered to play an important role for maintenance of type 2 inflammation in atopic dermatitis (AD), studies on basophils in AD patients are limited. Some studies have reported the activation status, including CD203c and CD63, of peripheral blood basophils in AD patients. OBJECTIVE: To examine the features of circulating basophils in AD patients by assessing and comparing cell surface marker expressions, total serum IgE, and basophil responsiveness to stimulation between AD patients and healthy controls (HCs). In addition, to examine the correlations among AD severity, laboratory factors, and features of basophils. METHODS: Blood samples from 38 AD patients and 21 HCs were analyzed. Basophil response markers CD203c and CD63, and expression of surface-bound IgE and FcεRI on basophils were measured. CD203c and CD63 expressions induced by stimulation with anti-IgE and anti-FcεRI antibodies were measured. Clinical/laboratory factors including total serum IgE were examined for correlations with these basophil parameters. RESULTS: Basophils in AD patients were activated spontaneously without stimulation and exhibited low responsiveness to anti-IgE antibody stimulation. Responsiveness to anti-FcεRI stimulation was higher than anti-IgE stimulation, contrary to HCs. FcεRI expression on basophils was higher in AD patients than in HCs, although surface-bound IgE on basophils was equivalent. Total serum IgE had negative correlations with surface-bound IgE and CD63 responsiveness to anti-IgE stimulation. CONCLUSIONS: Our findings illustrate the characteristic basophil status in AD. Despite high serum IgE and high basophil FcεRI expression, surface-bound IgE on basophils remained relatively low and basophils were spontaneously activated under steady-state conditions. 1 | INTRODUCTION Atopic dermatitis (AD) is a disease characterized by lesions involving eczema with pruritus, which are repeatedly exacerbated and ameliorated. 1 Immunologically, AD is characterized by overexpression of T helper 2 (Th2) cytokines including interleukin (IL)-4 and IL-13. Therefore, many AD patients have a predisposition toward allergy, i.e., a condition that readily produces allergen-specific IgE antibodies that are activated and produced by Th2 cytokines. 2

show abstract

“…AD causes health-related burdens associated with pruritus and poor quality of life [1]. A systematic review and meta-analysis showed that parental history of AD increased the risk of AD in the offspring (pooled odds ratio: 3.30, 95% con dence interval [CI]: 2.45-4.42) [2].…”

Section: Introductionmentioning

confidence: 99%

“…According to an epidemiological study, which was conducted globally between 1994 and 1996, the prevalence of AD was 7.3% among children aged 6 to 7 years old and 7.4% among those aged 13 to 14 years old [3]. The prevalence of AD as con rmed by a physician's examination in Japan is 12.8% in children aged 4 months old, 9.8% at 1.5 years old, and 13.2% at 3 years old, [1,4]. We previously reported that 32.3% of children had been diagnosed with AD until the age of 9 years and identi ed four phenotypes of AD in Tokyo, Japan [5].…”

Section: Introductionmentioning

confidence: 99%

Effective Prevention of Atopic Dermatitis by Applying Fam’s Baby Moisturizer Twice Daily or Once Daily Compared with 2e Moisturizer Once Daily in High-Risk Neonates: Study Protocol for A Randomized, Blinded, Parallel, Three Group, Phase II Trial (PAF Study)

Inuzuka¹,

Yamamoto‐Hanada²,

Pak³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundAtopic dermatitis (AD) is a chronic and inflammatory skin disease that commonly affects young children. AD causes health-related burdens associated with pruritus and poor quality of life. The efficacy of moisturizer application shows inconsistency on primary prevention of AD according to previous randomized, controlled trials. Which moisturizer is effective and how often moisturizer should be applied to prevent development of AD in infants remain unclear. We hypothesize that twice daily application of moisturizer using Fam’s Baby is more effective than once daily application and that a sufficient amount of moisturizer application is effective for preventing development of AD in neonates and infants. Therefore, this study aimed to examine whether applying Fam’s Baby twice daily or once daily prevents AD compared with 2e moisturizer once daily in neonates and infants with at least one parent or sibling who has had atopic dermatitis.MethodsThis study is a single-center, three-parallel group, assessor-blind, superiority, individually randomized, controlled, phase II trial. A newborn with at least one parent or sibling who has had AD is randomly assigned to application of Fam’s Baby twice daily, Fam’s Baby once daily, or 2e once daily in a 1:1:1 ratio until 32 weeks old. The primary outcome is the time to the first onset of AD during administration of the moisturizer.DiscussionThis is the first phase II randomized, controlled trial in Japan to investigate whether applying moisturizer (Fam’s Baby) twice daily or once daily can prevent the incidence of AD compared with another moisturizer (2e) once daily in high-risk neonates. In this study, we will use 2e once daily as control moisturizer to confirm the efficacy for primary prevention of AD as found in our previous trial. Evaluation of application of moisturizers for preventing AD in this study is expected to contribute to a reduction in the prevalence of AD and a reduction in health care costs. Trial registrationJapan Registry of Clinical Trials (jRCT); ID: jRCTs031200070. Registered on 20 July 2020.

show abstract

Japanese guidelines for atopic dermatitis 2020

Cited by 139 publications

References 65 publications

Ways of Optimizing the Diagnostics of Food Allergies in Children Based on the Clinical and Immunological Criteria

Ways of Optimizing the Diagnostics of Food Allergies in Children Based on the Clinical and Immunological Criteria

Activated steady status and distinctive FcεRI-mediated responsiveness in basophils of atopic dermatitis

Effective Prevention of Atopic Dermatitis by Applying Fam’s Baby Moisturizer Twice Daily or Once Daily Compared with 2e Moisturizer Once Daily in High-Risk Neonates: Study Protocol for A Randomized, Blinded, Parallel, Three Group, Phase II Trial (PAF Study)

Contact Info

Product

Resources

About